{"id":6882,"date":"2024-05-06T09:00:51","date_gmt":"2024-05-06T09:00:51","guid":{"rendered":"https:\/\/oncopeptides.com\/investors\/aktien\/nyemissioner\/foretradesemission-2024\/"},"modified":"2026-03-19T15:07:52","modified_gmt":"2026-03-19T15:07:52","slug":"foretradesemission-2024","status":"publish","type":"investors","link":"https:\/\/oncopeptides.com\/sv\/investerare\/aktien\/nyemissioner\/foretradesemission-2024\/","title":{"rendered":"F\u00f6retr\u00e4desemission 2024"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"6882\" class=\"elementor elementor-6882 elementor-6709\" data-elementor-post-type=\"investors\">\n\t\t\t\t<style>\n                .elementor-element-046e80f{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-046e80f e-flex e-con-boxed e-con e-parent\" data-id=\"046e80f\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<style>\n                .elementor-element-e81e407{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-e81e407 e-con-full haus-2-1 e-flex e-con e-child\" data-id=\"e81e407\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e2df820 elementor-widget elementor-widget-heading\" data-id=\"e2df820\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">F\u00f6retr\u00e4desemission<br><span style=\"color: var(--color-orange)\">2024<\/span><\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6ec5928 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"6ec5928\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-536f746{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-536f746 e-con-full e-flex e-con e-child\" data-id=\"536f746\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-09ad44c elementor-widget elementor-widget-text-editor\" data-id=\"09ad44c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h2>Oncopeptides offentligg\u00f6r slutgiltigt utfall i den fullt garanterade f\u00f6retr\u00e4desemissionen<\/h2>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2a581d4 elementor-widget elementor-widget-text-editor\" data-id=\"2a581d4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>6 maj 2024 \u2013 Regulatorisk pressrelease \u2013 Oncopeptides AB (publ) offentligg\u00f6r h\u00e4rmed det slutgiltiga utfallet i den fullt garanterade f\u00f6retr\u00e4desemissionen om cirka 314 miljoner kronor f\u00f6re avdrag f\u00f6r kostnader h\u00e4nf\u00f6rliga till f\u00f6retr\u00e4desemissionen (\u201dF\u00f6retr\u00e4desemissionen\u201d). Teckningsperioden i F\u00f6retr\u00e4desemissionen avslutades den 3 maj 2024. Det slutgiltiga utfallet visar att 98 415 644 stamaktier, motsvarande cirka 82 procent av de erbjudna stamaktierna, har tecknats med st\u00f6d av teckningsr\u00e4tter i F\u00f6retr\u00e4desemissionen. D\u00e4rtill har anm\u00e4lningar f\u00f6r teckning utan teckningsr\u00e4tter av 14 909 424 stamaktier, motsvarande cirka 12 procent av de erbjudna stamaktierna, mottagits. Tillsammans motsvarar teckning med st\u00f6d av teckningsr\u00e4tter och teckningsanm\u00e4lningar utan st\u00f6d av teckningsr\u00e4tter cirka 94 procent av de erbjudna stamaktierna i F\u00f6retr\u00e4desemissionen. D\u00e4rmed kommer garanti\u00e5taganden om 7 261 101 stamaktier, motsvarande cirka 6 procent av de erbjudna stamaktierna, att utnyttjas. F\u00f6retr\u00e4desemissionen kommer att tillf\u00f6ra Bolaget cirka 314 miljoner kronor f\u00f6re avdrag f\u00f6r kostnader h\u00e4nf\u00f6rliga till F\u00f6retr\u00e4desemissionen.      <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-56f15e5 elementor-widget elementor-widget-button\" data-id=\"56f15e5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"#\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">L\u00e4s pressmeddelandet<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-827b613 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"827b613\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-5df8ccf{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-5df8ccf e-con-full e-flex e-con e-child\" data-id=\"5df8ccf\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-adb040f elementor-widget elementor-widget-heading\" data-id=\"adb040f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Fr\u00e5gor och svar f\u00f6r investerare<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-297e178 elementor-widget elementor-widget-text-editor\" data-id=\"297e178\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h3>1. Vad \u00e4r detta?<\/h3><p><strong>Svar:<\/strong> Oncopeptides har g\u00e5tt ut med att man genomf\u00f6r en fullt garanterad f\u00f6retr\u00e4desemission om cirka 300 miljoner kronor med st\u00f6d av v\u00e5ra st\u00f6rre aktie\u00e4gare. Vi g\u00f6r den d\u00e5 vi har ett behov av kapital f\u00f6r att ta oss fram till 2026, d\u00e5 vi r\u00e4knar med att vara l\u00f6nsamma. <\/p><h3>2. Vad kommer pengarna att anv\u00e4ndas till?<\/h3><p><strong>Svar:<\/strong> F\u00f6r den som f\u00f6ljt oss p\u00e5 senaste tiden \u00e4r det f\u00f6rhoppningsvis tydligt att v\u00e5rt absoluta fokus ligger p\u00e5 kommersialiseringen i Europa, och det \u00e4r ocks\u00e5 dit pengarna kommer att g\u00e5.<\/p><p>Ut\u00f6ver det kommer vi ocks\u00e5 att forts\u00e4tta driva utvecklingen av v\u00e5r pipeline fram\u00e5t, medan vi ocks\u00e5 forts\u00e4tter arbeta f\u00f6r att finna marknader utanf\u00f6r Europa f\u00f6r Pepaxti, det \u00e4r dock inget som driver s\u00e4rskilt mycket kostnader d\u00e5 vi arbetar mot partnerskap.<\/p><h3>3. Vad inneb\u00e4r en f\u00f6retr\u00e4desemission?<\/h3><p><strong>Svar:<\/strong> En f\u00f6retr\u00e4desemission \u00e4r ett s\u00e4tt f\u00f6r ett bolag att ta in mer pengar genom att s\u00e4lja fler aktier, med f\u00f6retr\u00e4de till nuvarande aktie\u00e4gare. Tanken \u00e4r lite som en \u201df\u00f6rsta tjing\u201d f\u00f6r de som redan har investerat i f\u00f6retaget. <\/p><p>F\u00f6r att g\u00f6ra det r\u00e4ttvist baseras chansen att k\u00f6pa p\u00e5 hur m\u00e5nga aktier man redan \u00e4ger. Om du till exempel \u00e4ger 10% av f\u00f6retaget, f\u00e5r du chansen att k\u00f6pa 10% av de nya aktierna f\u00f6rst. Detta ger nuvarande \u00e4gare en chans att inte f\u00e5 sin andel utsp\u00e4dd, det vill s\u00e4ga att deras \u00e4gande inte minskar i procent eftersom det finns fler aktier tillg\u00e4ngliga efter emissionen.  <\/p><p>F\u00f6r att f\u00f6rs\u00e4kra sig om att nyemissionen blir framg\u00e5ngsrik s\u00e4tts emissionskursen under nuvarande aktiekurs. Existerande aktie\u00e4gare f\u00e5r d\u00e4rmed en \u201drabatt\u201d p\u00e5 de nyemitterade aktierna. En aktie\u00e4gare kan v\u00e4lja mellan att antingen delta i nyemissionen eller att s\u00e4lja teckningsr\u00e4tterna. I annat fall g\u00e5r \u201drabatten\u201d, skillnaden mellan aktiekursen och emissionskursen, f\u00f6rlorad. V\u00e4ljer aktie\u00e4garen att inte teckna sig f\u00f6r nyemissionen minskar ocks\u00e5 \u00e4garandelen i bolaget.    <\/p><h3>4. Hur p\u00e5verkar emissionen mitt nuvarande \u00e4gande?<\/h3><p><strong>Svar:<\/strong> F\u00f6rutsatt att en aktie\u00e4gare v\u00e4ljer att teckna sig f\u00f6r emissionen kommer \u00e4gandet att best\u00e5 med samma procentuella andel som tidigare av bolagets samtliga aktier.<\/p><h3>5. Vad \u00e4r teckningskursen f\u00f6r nya aktier?<\/h3><p><strong>Svar:<\/strong> De slutliga villkoren f\u00f6r f\u00f6retr\u00e4desemissionen, inklusive teckningskurs och antal nyemitterade aktier kommer beslutas av styrelsen senast fem vardagar f\u00f6re avst\u00e4mningsdagen f\u00f6r f\u00f6retr\u00e4desemissionen och sedan offentligg\u00f6ras i ett prospekt. Prospektet \u00e4r t\u00e4nkt att offentligg\u00f6ras 17 april. <\/p><h3>6. Hur best\u00e4ms teckningskursen?<\/h3><p><strong>Svar:<\/strong> Teckningskursen vid en nyemission best\u00e4ms genom en kombination av flera faktorer, d\u00e4ribland marknadens v\u00e4rdering och efterfr\u00e5gan fr\u00e5n investerare.<\/p><h3>7. Varf\u00f6r \u00e4r inte villkoren f\u00f6r emissionen tillg\u00e4ngliga \u00e4nnu?<\/h3><p><strong>Svar:<\/strong> Det korta svaret att vi vill l\u00e5ta marknaden ha en hand med i priss\u00e4ttningen av aktien. Detta \u00e4r ett vanligt uppl\u00e4gg d\u00e4r det exakta priset f\u00f6r att delta i f\u00f6retr\u00e4desemissionen s\u00e4tts f\u00f6rst n\u00e4rmare inp\u00e5 den extra bolagsst\u00e4mman och n\u00e4r teckningsperioden ska inledas. Anledningen \u00e4r att vi vill att rabatten blir lagom stor f\u00f6r emissionen och det kan man bed\u00f6ma med st\u00f6rre s\u00e4kerhet n\u00e4rmare inp\u00e5 att transaktionen ska genomf\u00f6ras.  <\/p><p>F\u00f6r att f\u00f6rs\u00e4kra sig om att nyemissionen blir framg\u00e5ngsrik s\u00e4tts emissionskursen typiskt sett under nuvarande aktiekurs, d.v.s. existerande aktie\u00e4gare f\u00e5r d\u00e4rmed en \u201drabatt\u201d p\u00e5 de nyemitterade aktierna. En aktie\u00e4gare kan v\u00e4lja mellan att antingen delta i nyemissionen eller att s\u00e4lja teckningsr\u00e4tterna. I annat fall g\u00e5r \u201drabatten\u201d, skillnaden mellan aktiekursen och emissionskursen, f\u00f6rlorad. V\u00e4ljer aktie\u00e4garen att inte teckna sig f\u00f6r nyemissionen minskar ocks\u00e5 \u00e4garandelen i bolaget.   <\/p><h3>8. Kommer det finnas m\u00f6jlighet att s\u00e4lja mina teckningsr\u00e4tter\/att k\u00f6pa fler teckningsr\u00e4tter?<\/h3><p><strong>Svar:<\/strong> Ja \u2013 det kommer g\u00e5 att handla med teckningsr\u00e4tter p\u00e5 Nasdaq Stockholm mellan den 19 april och 29 april.<\/p><h3>9. Vad h\u00e4nder om jag inte v\u00e4ljer att teckna mig f\u00f6r mina r\u00e4ttigheter?<\/h3><p><strong>Svar:<\/strong> Existerande aktie\u00e4gare b\u00f6r, om de inte v\u00e4ljer att teckna sig, s\u00e4lja sina teckningsr\u00e4tter f\u00f6re den 29 april d\u00e5 v\u00e4rdet i r\u00e4tterna annars g\u00e5r f\u00f6rlorat.<\/p><h3>10. Hur har bolagets ledning positionerat sig i emissionen? Kommer de att delta? <\/h3><p><strong>Svar:<\/strong> Den stora merparten av bolagets ledning har \u00e5tagit sig att delta i emissionen.<\/p><h3>11. Vad \u00e4r en stamaktie? Har jag det? <\/h3><p><strong>Svar:<\/strong> Ja, alla vanliga aktie\u00e4gare har vad som brukar kallas stamaktie.<\/p><h3>12. Vad \u00e4r en BTA?<\/h3><p><strong>Svar:<\/strong> I sammanhanget av en f\u00f6retr\u00e4desemission st\u00e5r BTA f\u00f6r \u201dBetald Tecknad Aktie\u201d. N\u00e4r en investerare v\u00e4ljer att delta i en f\u00f6retr\u00e4desemission och tecknar sig f\u00f6r nya aktier, kan det dr\u00f6ja en tid innan de nya aktierna \u00e4r registrerade hos Bolagsverket och investeraren formellt blir registrerad som \u00e4gare av aktierna. Under denna period, mellan betalning och registrering, erh\u00e5ller investeraren BTAs som ett bevis p\u00e5 att aktierna har tecknats och betalats, men \u00e4nnu inte registrerats.  <\/p><p>BTAer ger investeraren en r\u00e4ttighet att i framtiden erh\u00e5lla de faktiska aktierna. Dessa betalda och tecknade aktier kommer att handlas p\u00e5 b\u00f6rsen mellan 19 april och 13 maj, vilket ger investerarna m\u00f6jlighet att k\u00f6pa eller s\u00e4lja sina BTAer innan de omvandlas till vanliga aktier, efter att emissionen har registrerats och aktierna blivit utgivna. Detta sker f\u00f6r att ge likviditet och flexibilitet f\u00f6r de som deltar i emissionen.  <\/p><h3>13. N\u00e4r kommer prospekt att publiceras?<\/h3><p><strong>Svar:<\/strong> Ett prospekt med de slutliga villkoren f\u00f6r f\u00f6retr\u00e4desemissionen, inklusive teckningskurs och antal nyemitterade aktier kommer att offentligg\u00f6ras den 17 april.<\/p><h3>11.Var kan jag hitta mer information och detaljer om f\u00f6retr\u00e4desemissionen?<\/h3><p><strong>Svar:<\/strong> Inf\u00f6r eventuella investeringsbeslut h\u00e4nvisas f\u00f6rst och fr\u00e4mst till det prospekt som kommer att godk\u00e4nnas och offentligg\u00f6ras med anledning av f\u00f6retr\u00e4desemissionen och finnas tillg\u00e4ngligt p\u00e5 v\u00e5r hemsida, under Investerare. Du kan \u00e4ven ta kontakt med bolagets IR-chef David Augustsson. <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f3ba5d9 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"f3ba5d9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-167526f{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-167526f e-con-full e-flex e-con e-child\" data-id=\"167526f\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-5aa7ac0 elementor-widget elementor-widget-text-editor\" data-id=\"5aa7ac0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>DENNA INFORMATION F\u00c5R INTE OFFENTLIGG\u00d6RAS, PUBLICERAS ELLER DISTRIBUERAS, DIREKT ELLER INDIREKT, I ELLER TILL AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SINGAPORE, SYDAFRIKA, USA ELLER N\u00c5GON ANNAN JURISDIKTION D\u00c4R S\u00c5DAN \u00c5TG\u00c4RD HELT ELLER DELVIS \u00c4R F\u00d6REM\u00c5L F\u00d6R LEGALA RESTRIKTIONER. DENNA INFORMATION UTG\u00d6R INTE ETT ERBJUDANDE ATT F\u00d6RV\u00c4RVA V\u00c4RDEPAPPER I ONCOPEPTIDES AB (PUBL). <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d464802 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"d464802\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-ecfc237{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-ecfc237 e-con-full e-flex e-con e-child\" data-id=\"ecfc237\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-f693638 elementor-widget elementor-widget-heading\" data-id=\"f693638\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Information om anm\u00e4lningssedlarna<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-35b6cfa elementor-widget elementor-widget-text-editor\" data-id=\"35b6cfa\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>V\u00e4nligen notera att anm\u00e4lningssedlarna nedan \u00e4r f\u00f6r direkt\u00e4gande aktie\u00e4gare. \u00c4ger du aktier via din bank, exempelvis Avanza eller Nordnet, kommer du att kunna teckna dig den v\u00e4gen. Teckningsr\u00e4tter f\u00f6r nuvarande aktie\u00e4gare kommer att distribueras den 19 april 2024.  <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-cd34bdd{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-cd34bdd e-con-full e-flex e-con e-child\" data-id=\"cd34bdd\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-05755fd elementor-widget elementor-widget-heading\" data-id=\"05755fd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Dokument till f\u00f6retr\u00e4desemissionen<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a6ff451 elementor-position-inline-end elementor-view-default elementor-widget elementor-widget-icon-box\" data-id=\"a6ff451\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-box.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-icon-box-wrapper\">\n\n\t\t\t\t\t\t<div class=\"elementor-icon-box-icon\">\n\t\t\t\t<a href=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/03\/oncopeptides-prospekt-foretradesemission-maj-2024.pdf\" target=\"_blank\" class=\"elementor-icon\" tabindex=\"-1\" aria-label=\"Prospekt f\u00f6retr\u00e4desemission maj 2024\">\n\t\t\t\t<i aria-hidden=\"true\" class=\"onco onco-Download-3\"><\/i>\t\t\t\t<\/a>\n\t\t\t<\/div>\n\t\t\t\n\t\t\t\t\t\t<div class=\"elementor-icon-box-content\">\n\n\t\t\t\t\t\t\t\t\t<h3 class=\"elementor-icon-box-title\">\n\t\t\t\t\t\t<a href=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/03\/oncopeptides-prospekt-foretradesemission-maj-2024.pdf\" target=\"_blank\" >\n\t\t\t\t\t\t\tProspekt f\u00f6retr\u00e4desemission maj 2024\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h3>\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t<p class=\"elementor-icon-box-description\">\n\t\t\t\t\t\tpdf, 1 MB\t\t\t\t\t<\/p>\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-12c63b2 elementor-position-inline-end elementor-view-default elementor-widget elementor-widget-icon-box\" data-id=\"12c63b2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-box.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-icon-box-wrapper\">\n\n\t\t\t\t\t\t<div class=\"elementor-icon-box-icon\">\n\t\t\t\t<a href=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/03\/oncopeptides-anmalningssedel-med-foretradesratt-sv2024.pdf\" target=\"_blank\" class=\"elementor-icon\" tabindex=\"-1\" aria-label=\"Oncopeptides anm\u00e4lningssedel - Med F\u00f6retr\u00e4desr\u00e4tt\">\n\t\t\t\t<i aria-hidden=\"true\" class=\"onco onco-Download-3\"><\/i>\t\t\t\t<\/a>\n\t\t\t<\/div>\n\t\t\t\n\t\t\t\t\t\t<div class=\"elementor-icon-box-content\">\n\n\t\t\t\t\t\t\t\t\t<h3 class=\"elementor-icon-box-title\">\n\t\t\t\t\t\t<a href=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/03\/oncopeptides-anmalningssedel-med-foretradesratt-sv2024.pdf\" target=\"_blank\" >\n\t\t\t\t\t\t\tOncopeptides anm\u00e4lningssedel - Med F\u00f6retr\u00e4desr\u00e4tt\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h3>\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t<p class=\"elementor-icon-box-description\">\n\t\t\t\t\t\tpdf, 304 KB\t\t\t\t\t<\/p>\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-9319443 elementor-position-inline-end elementor-view-default elementor-widget elementor-widget-icon-box\" data-id=\"9319443\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-box.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-icon-box-wrapper\">\n\n\t\t\t\t\t\t<div class=\"elementor-icon-box-icon\">\n\t\t\t\t<a href=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/03\/oncopeptides-anmalningssedel-utan-foretradesratt-sv2024.pdf\" target=\"_blank\" class=\"elementor-icon\" tabindex=\"-1\" aria-label=\"Oncopeptides anm\u00e4lningssedel - Utan F\u00f6retr\u00e4desr\u00e4tt\">\n\t\t\t\t<i aria-hidden=\"true\" class=\"onco onco-Download-3\"><\/i>\t\t\t\t<\/a>\n\t\t\t<\/div>\n\t\t\t\n\t\t\t\t\t\t<div class=\"elementor-icon-box-content\">\n\n\t\t\t\t\t\t\t\t\t<h3 class=\"elementor-icon-box-title\">\n\t\t\t\t\t\t<a href=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/03\/oncopeptides-anmalningssedel-utan-foretradesratt-sv2024.pdf\" target=\"_blank\" >\n\t\t\t\t\t\t\tOncopeptides anm\u00e4lningssedel - Utan F\u00f6retr\u00e4desr\u00e4tt\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h3>\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t<p class=\"elementor-icon-box-description\">\n\t\t\t\t\t\tpdf, 323 KB\t\t\t\t\t<\/p>\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-71a8f6a elementor-position-inline-end elementor-view-default elementor-widget elementor-widget-icon-box\" data-id=\"71a8f6a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-box.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-icon-box-wrapper\">\n\n\t\t\t\t\t\t<div class=\"elementor-icon-box-icon\">\n\t\t\t\t<a href=\"\" target=\"_blank\" class=\"elementor-icon\" tabindex=\"-1\" aria-label=\"Registreringsbevis Oncopeptides AB\">\n\t\t\t\t<i aria-hidden=\"true\" class=\"onco onco-Download-3\"><\/i>\t\t\t\t<\/a>\n\t\t\t<\/div>\n\t\t\t\n\t\t\t\t\t\t<div class=\"elementor-icon-box-content\">\n\n\t\t\t\t\t\t\t\t\t<h3 class=\"elementor-icon-box-title\">\n\t\t\t\t\t\t<a href=\"\" target=\"_blank\" >\n\t\t\t\t\t\t\tRegistreringsbevis Oncopeptides AB\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h3>\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t<p class=\"elementor-icon-box-description\">\n\t\t\t\t\t\tpdf, 67 KB\t\t\t\t\t<\/p>\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0b16c6f dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"0b16c6f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-341e670{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-341e670 e-con-full e-flex e-con e-child\" data-id=\"341e670\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-f6017f0 elementor-widget elementor-widget-text-editor\" data-id=\"f6017f0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Pressmeddelande<\/p><h2>Oncopeptides offentligg\u00f6r prospekt avseende f\u00f6retr\u00e4desemissionen<\/h2><p>17 april2024 \u2013 Regulatoriskt pressmeddelande<\/p><p>Oncopeptides AB (publ) offentliggjorde den 13 mars 2024 att styrelsen beslutat om en fullt garanterad f\u00f6retr\u00e4desemission om cirka 314 miljoner kronor f\u00f6re avdrag f\u00f6r kostnader h\u00e4nf\u00f6rliga till f\u00f6retr\u00e4desemissionen (\u201dF\u00f6retr\u00e4desemissionen\u201d).<\/p><p>TProspektet avseende F\u00f6retr\u00e4desemissionen har idag, den 17 april 2024, godk\u00e4nts och registrerats av Finansinspektionen och finns tillg\u00e4ngligt p\u00e5 Oncopeptides hemsida och p\u00e5 Carnegie Investment Bank AB (publ)s hemsida. Prospektet kommer \u00e4ven g\u00f6ras tillg\u00e4ngligt p\u00e5 Finansinspektionens hemsida. <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-8e76689 elementor-widget elementor-widget-button\" data-id=\"8e76689\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/oncopeptides.com\/sv\/pressmeddelanden\/oncopeptides-offentliggor-prospekt-avseende-foretradesemissionen\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">L\u00e4s pressmeddelandet<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-66bd8ea dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"66bd8ea\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-f553f04{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-f553f04 e-con-full e-flex e-con e-child\" data-id=\"f553f04\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-8484c91 elementor-widget elementor-widget-heading\" data-id=\"8484c91\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Viktiga datum<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3caaacb elementor-widget elementor-widget-image\" data-id=\"3caaacb\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<webien-image class=\" has-thumb ratio-original\">\r\n\t<img fetchpriority=\"high\" decoding=\"async\" src=\"https:\/\/c1.webien.cloud\/pixel.webp\" width=\"1024\" height=\"536\" data-srcset=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2024\/03\/1-1024x536-1.png\" data-original=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2024\/03\/1-1024x536-1.png\" data-optimize=\"1\" data-useoriginal=\"0\" data-ratio=\"none\" data-sizes=\"auto\" data-focus=\"attention\" class=\"main lazyload\" title=\"5-1024&#215;536\" alt=\"\" \/>\r\n\t\r\n\t<img decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/wrooom.webien.io\/eyJpbWFnZVVybCI6Imh0dHBzOi8vb25jb3BlcHRpZGVzLmNvbS93cC1jb250ZW50L3VwbG9hZHMvMjAyNC8wMy8xLTEwMjR4NTM2LTEucG5nIiwicHVibGljS2V5Ijoibm9LZXkiLCJlZGl0cyI6eyJyZXNpemUiOnsid2lkdGgiOjE1MCwiaGVpZ2h0IjoxNTAsImZpdCI6Imluc2lkZSIsInBvc2l0aW9uIjoiYXR0ZW50aW9uIiwid2l0aG91dEVubGFyZ2VtZW50Ijp0cnVlfSwiYmx1ciI6M319\" class=\"thumb\" \/>\r\n\t<\/webien-image>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e9e1acb elementor-widget elementor-widget-image\" data-id=\"e9e1acb\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<webien-image class=\" has-thumb ratio-original\">\r\n\t<img decoding=\"async\" src=\"https:\/\/c1.webien.cloud\/pixel.webp\" width=\"1024\" height=\"536\" data-srcset=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2024\/03\/2-1024x536-1.png\" data-original=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2024\/03\/2-1024x536-1.png\" data-optimize=\"1\" data-useoriginal=\"0\" data-ratio=\"none\" data-sizes=\"auto\" data-focus=\"attention\" class=\"main lazyload\" title=\"6-1024&#215;536\" alt=\"\" \/>\r\n\t\r\n\t<img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/wrooom.webien.io\/eyJpbWFnZVVybCI6Imh0dHBzOi8vb25jb3BlcHRpZGVzLmNvbS93cC1jb250ZW50L3VwbG9hZHMvMjAyNC8wMy8yLTEwMjR4NTM2LTEucG5nIiwicHVibGljS2V5Ijoibm9LZXkiLCJlZGl0cyI6eyJyZXNpemUiOnsid2lkdGgiOjE1MCwiaGVpZ2h0IjoxNTAsImZpdCI6Imluc2lkZSIsInBvc2l0aW9uIjoiYXR0ZW50aW9uIiwid2l0aG91dEVubGFyZ2VtZW50Ijp0cnVlfSwiYmx1ciI6M319\" class=\"thumb\" \/>\r\n\t<\/webien-image>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-8d7e800 elementor-widget elementor-widget-image\" data-id=\"8d7e800\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<webien-image class=\" has-thumb ratio-original\">\r\n\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/c1.webien.cloud\/pixel.webp\" width=\"1024\" height=\"536\" data-srcset=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2024\/03\/3-1024x536-1.png\" data-original=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2024\/03\/3-1024x536-1.png\" data-optimize=\"1\" data-useoriginal=\"0\" data-ratio=\"none\" data-sizes=\"auto\" data-focus=\"attention\" class=\"main lazyload\" title=\"7-1024&#215;536\" alt=\"\" \/>\r\n\t\r\n\t<img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/wrooom.webien.io\/eyJpbWFnZVVybCI6Imh0dHBzOi8vb25jb3BlcHRpZGVzLmNvbS93cC1jb250ZW50L3VwbG9hZHMvMjAyNC8wMy8zLTEwMjR4NTM2LTEucG5nIiwicHVibGljS2V5Ijoibm9LZXkiLCJlZGl0cyI6eyJyZXNpemUiOnsid2lkdGgiOjE1MCwiaGVpZ2h0IjoxNTAsImZpdCI6Imluc2lkZSIsInBvc2l0aW9uIjoiYXR0ZW50aW9uIiwid2l0aG91dEVubGFyZ2VtZW50Ijp0cnVlfSwiYmx1ciI6M319\" class=\"thumb\" \/>\r\n\t<\/webien-image>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-40bd2bc dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"40bd2bc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-88de5c5{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-88de5c5 e-con-full e-flex e-con e-child\" data-id=\"88de5c5\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6341bc0 elementor-widget elementor-widget-text-editor\" data-id=\"6341bc0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Pressmeddelande<\/p><h2>Oncopeptides offentligg\u00f6r slutliga villkor f\u00f6r den fullt garanterade f\u00f6retr\u00e4desemissionen<\/h2><p>8 april 2024 \u2013 Regulatoriskt pressmeddelande<\/p><p>Den 13 mars 2024 offentliggjorde Oncopeptides AB (publ) att styrelsen beslutat om en fullt garanterad f\u00f6retr\u00e4desemission om cirka 314 miljoner kronor, under f\u00f6ruts\u00e4ttning att beslutet godk\u00e4nns p\u00e5 extra bolagsst\u00e4mman den 15 april 2024 (\u201dF\u00f6retr\u00e4desemissionen\u201d). Syftet med F\u00f6retr\u00e4desemissionen \u00e4r att tillhandah\u00e5lla ytterligare kapital f\u00f6r att i f\u00f6rsta hand finansiera den p\u00e5g\u00e5ende kommersialiseringen av Pepaxti\u00ae i Europa fram till dess att Bolaget r\u00e4knar med att bli l\u00f6nsamt i slutet av 2026, samt \u00e4ven framdrivandet av Bolagets portf\u00f6lj av prekliniska projekt, och samtidigt s\u00f6ka partnerskap f\u00f6r att st\u00f6tta expanderingen av f\u00f6rs\u00e4ljningen av Pepaxti geografiskt utanf\u00f6r Europa. Styrelsen har idag beslutat om de slutliga villkoren f\u00f6r F\u00f6retr\u00e4desemissionen, inklusive teckningskurs och antal nya aktier som h\u00f6gst kommer att emitteras.  <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ee168c5 elementor-widget elementor-widget-button\" data-id=\"ee168c5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/oncopeptides.com\/sv\/pressmeddelanden\/oncopeptides-offentliggor-slutliga-villkor-for-den-fullt-garanterade-foretradesemissionen\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">L\u00e4s pressmeddelandet<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1731631 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"1731631\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-3023f3e{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-3023f3e e-con-full e-flex e-con e-child\" data-id=\"3023f3e\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-89a4eff elementor-widget elementor-widget-text-editor\" data-id=\"89a4eff\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h2>Extra bolagsst\u00e4mma 2024<\/h2>\nOncopeptides extra bolagsst\u00e4mma 2024 avseende beslut om godk\u00e4nnande av styrelsens beslut om nyemission av stamaktier med f\u00f6retr\u00e4desr\u00e4tt f\u00f6r aktie\u00e4garna, h\u00f6lls p\u00e5 T\u00e4ndstickspalatset, 111 53 Stockholm den 15 april 2024. \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e561ccc elementor-widget elementor-widget-button\" data-id=\"e561ccc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/oncopeptides.com\/sv\/investerare\/bolagsstamma\/extra-bolagsstamma-2024\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">All information runt Extra bolagsst\u00e4mma 2024<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-adccbde dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"adccbde\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-1bd8994{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-1bd8994 e-con-full e-flex e-con e-child\" data-id=\"1bd8994\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-bc797b2 elementor-widget elementor-widget-heading\" data-id=\"bc797b2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Oncopeptalks om f\u00f6retr\u00e4desemissionen<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-9402000 elementor-widget elementor-widget-image\" data-id=\"9402000\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<webien-image class=\" has-thumb ratio-original\">\r\n\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/c1.webien.cloud\/pixel.webp\" width=\"2557\" height=\"1439\" data-srcset=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2024\/03\/skarmbild-2026-03-18-112739-1024x576.png\" data-original=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2024\/03\/skarmbild-2026-03-18-112739-1024x576.png\" data-optimize=\"1\" data-useoriginal=\"0\" data-ratio=\"none\" data-sizes=\"auto\" data-focus=\"attention\" class=\"main lazyload\" title=\"Sk\u00e4rmbild 2026-03-18 112739\" alt=\"\" \/>\r\n\t\r\n\t<img loading=\"lazy\" decoding=\"async\" width=\"2557\" height=\"1439\" src=\"https:\/\/wrooom.webien.io\/eyJpbWFnZVVybCI6Imh0dHBzOi8vb25jb3BlcHRpZGVzLmNvbS93cC1jb250ZW50L3VwbG9hZHMvMjAyNC8wMy9za2FybWJpbGQtMjAyNi0wMy0xOC0xMTI3MzktMTAyNHg1NzYucG5nIiwicHVibGljS2V5Ijoibm9LZXkiLCJlZGl0cyI6eyJyZXNpemUiOnsid2lkdGgiOjE1MCwiaGVpZ2h0IjoxNTAsImZpdCI6Imluc2lkZSIsInBvc2l0aW9uIjoiYXR0ZW50aW9uIiwid2l0aG91dEVubGFyZ2VtZW50Ijp0cnVlfSwiYmx1ciI6M319\" class=\"thumb\" \/>\r\n\t<\/webien-image>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-699a6f1 elementor-widget elementor-widget-text-editor\" data-id=\"699a6f1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>13 mars 2024 \u2013 H\u00f6r Sofia Heigis, vd, och Henrik Bergentoft, CFO, ber\u00e4tta om varf\u00f6r Oncopeptides genomf\u00f6r en nyemission, vart pengarna ska g\u00e5, vad en f\u00f6retr\u00e4desemission egentligen \u00e4r och vad du som nuvarande eller potentiell aktie\u00e4gare b\u00f6r t\u00e4nka p\u00e5.<\/p><p>.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4514bd1 elementor-widget elementor-widget-button\" data-id=\"4514bd1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/oncopeptides.com\/sv\/oncopeptalks\/oncopeptalks-om-bolagets-foretradesemission\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Se avsnittet<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-416a542 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"416a542\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-ee09397{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-ee09397 e-con-full e-flex e-con e-child\" data-id=\"ee09397\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-f3e00ec elementor-widget elementor-widget-text-editor\" data-id=\"f3e00ec\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Pressmeddelande<\/p><h2>Oncopeptides genomf\u00f6r en fullt garanterad f\u00f6retr\u00e4desemission om cirka 300 miljoner kronor f\u00f6r att n\u00e5 l\u00f6nsamhet under 2026<\/h2><p>13 mars 2024 \u2013 Regulatoriskt pressmeddelande<\/p><p>Oncopeptides AB (publ) meddelar att styrelsen idag har beslutat att genomf\u00f6ra en fullt garanterad nyemission om cirka 300 miljoner kronor med f\u00f6retr\u00e4desr\u00e4tt f\u00f6r Bolagets befintliga stamaktie\u00e4gare (\u201dF\u00f6retr\u00e4desemissionen\u201d), under f\u00f6ruts\u00e4ttning att beslutet godk\u00e4nns p\u00e5 en extra bolagsst\u00e4mma som planeras att h\u00e5llas den 15 april 2024. Syftet med F\u00f6retr\u00e4desemissionen \u00e4r att tillhandah\u00e5lla ytterligare kapital f\u00f6r i f\u00f6rsta hand finansiera den p\u00e5g\u00e5ende kommersialiseringen av Pepaxti\u00ae i Europa fram till dess att Bolaget r\u00e4knar med att bli kassafl\u00f6despositivt i slutet av 2026, samt \u00e4ven framdrivandet av Bolagets portf\u00f6lj av prekliniska projekt, och samtidigt s\u00f6ka partnerskap f\u00f6r att st\u00f6tta expanderingen av f\u00f6rs\u00e4ljningen av Pepaxti geografiskt utanf\u00f6r Europa. <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-fd49ec3 elementor-widget elementor-widget-button\" data-id=\"fd49ec3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/oncopeptides.com\/sv\/pressmeddelanden\/oncopeptides-genomfor-en-fullt-garanterad-foretradesemission-om-cirka-300-miljoner-kronor-for-att-na-lonsamhet-under-2026\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">L\u00e4s pressmeddelandet<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-59623b5 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"59623b5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-aac81c9 elementor-widget elementor-widget-spacer\" data-id=\"aac81c9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"featured_media":0,"parent":5698,"menu_order":0,"template":"","meta":{"_acf_changed":false},"protected-content":[341],"class_list":["post-6882","investors","type-investors","status-publish","hentry","protected-content-show-disclaimer"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/6882","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors"}],"about":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/types\/investors"}],"version-history":[{"count":9,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/6882\/revisions"}],"predecessor-version":[{"id":6894,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/6882\/revisions\/6894"}],"up":[{"embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/5698"}],"wp:attachment":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/media?parent=6882"}],"wp:term":[{"taxonomy":"protected-content","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/protected-content?post=6882"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}